Literature DB >> 31989151

Network Analysis Indicates That Avolition Is the Most Central Domain for the Successful Treatment of Negative Symptoms: Evidence From the Roluperidone Randomized Clinical Trial.

Gregory P Strauss1, Farnaz Zamani Esfahlani2, Hiroki Sayama2, Brian Kirkpatrick3, Mark G Opler4, Jay B Saoud5, Michael Davidson5,6, Remy Luthringer5.   

Abstract

A recent conceptual development in schizophrenia is to view its manifestations as interactive networks rather than individual symptoms. Negative symptoms, which are associated with poor functional outcome and reduced rates of recovery, represent a critical need in schizophrenia therapeutics. MIN101 (roluperidone), a compound in development, demonstrated efficacy in the treatment of negative symptoms in schizophrenia. However, it is unclear how the drug achieved its effect from a network perspective. The current study evaluated the efficacy of roluperidone from a network perspective. In this randomized clinical trial, participants with schizophrenia and moderate to severe negative symptoms were randomly assigned to roluperidone 32 mg (n = 78), 64 mg (n = 83), or placebo (N = 83). Macroscopic network properties were evaluated to determine whether roluperidone altered the overall density of the interconnections among symptoms. Microscopic properties were evaluated to examine which individual symptoms were most influential (ie, interconnected) on other symptoms in the network and are responsible for successful treatment effects. Participants receiving roluperidone did not differ from those randomized to placebo on macroscopic properties. However, microscopic properties (degree and closeness centrality) indicated that avolition was highly central in patients receiving placebo and that roluperidone reduced this level of centrality. These findings suggest that decoupling the influence of motivational processes from other negative symptom domains is essential for producing global improvements. The search for pathophysiological mechanisms and targeted treatment development should be focused on avolition, with the expectation of improvement in the entire constellation of negative symptoms if avolition is effectively treated.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  amotivation; negative symptoms; psychosis; treatment

Mesh:

Substances:

Year:  2020        PMID: 31989151      PMCID: PMC7342174          DOI: 10.1093/schbul/sbz141

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  13 in total

Review 1.  Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions.

Authors:  Deanna M Barch; Erin C Dowd
Journal:  Schizophr Bull       Date:  2010-06-21       Impact factor: 9.306

2.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

3.  A network theory of mental disorders.

Authors:  Denny Borsboom
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

4.  Robustness and replicability of psychopathology networks.

Authors:  Denny Borsboom; Donald J Robinaugh; Mijke Rhemtulla; Angélique O J Cramer
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

Review 5.  Network analysis: an integrative approach to the structure of psychopathology.

Authors:  Denny Borsboom; Angélique O J Cramer
Journal:  Annu Rev Clin Psychol       Date:  2013       Impact factor: 18.561

6.  Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.

Authors:  Michael Davidson; Jay Saoud; Corinne Staner; Nadine Noel; Elisabeth Luthringer; Sandra Werner; Joseph Reilly; Jean-Yves Schaffhauser; Jonathan Rabinowitz; Mark Weiser; Remy Luthringer
Journal:  Am J Psychiatry       Date:  2017-07-28       Impact factor: 18.112

7.  The brief negative symptom scale (BNSS): Sensitivity to treatment effects.

Authors:  Brian Kirkpatrick; Jay B Saoud; Gregory P Strauss; Anthony O Ahmed; Kazunori Tatsumi; Mark Opler; Remy Luthringer; Michael Davidson
Journal:  Schizophr Res       Date:  2017-12-21       Impact factor: 4.939

Review 8.  Negative symptoms in schizophrenia: avolition and Occam's razor.

Authors:  George Foussias; Gary Remington
Journal:  Schizophr Bull       Date:  2008-07-21       Impact factor: 9.306

9.  Dissociation of hedonic reaction to reward and incentive motivation in an animal model of the negative symptoms of schizophrenia.

Authors:  Ryan D Ward; Eleanor H Simpson; Vanessa L Richards; Gita Deo; Kathleen Taylor; John I Glendinning; Eric R Kandel; Peter D Balsam
Journal:  Neuropsychopharmacology       Date:  2012-03-14       Impact factor: 7.853

10.  Using network analysis for the prediction of treatment dropout in patients with mood and anxiety disorders: A methodological proof-of-concept study.

Authors:  Wolfgang Lutz; Brian Schwartz; Stefan G Hofmann; Aaron J Fisher; Kristin Husen; Julian A Rubel
Journal:  Sci Rep       Date:  2018-05-18       Impact factor: 4.379

View more
  14 in total

Review 1.  A review of negative symptom assessment strategies in youth at clinical high-risk for psychosis.

Authors:  Gregory P Strauss; Andrea Pelletier-Baldelli; Katherine Frost Visser; Elaine F Walker; Vijay A Mittal
Journal:  Schizophr Res       Date:  2020-06-07       Impact factor: 4.939

2.  Symptom Structure in Schizophrenia: Implications of Latent Variable Modeling vs Network Analysis.

Authors:  Samuel J Abplanalp; Michael F Green
Journal:  Schizophr Bull       Date:  2022-05-07       Impact factor: 7.348

3.  Two Factors, Five Factors, or Both? External Validation Studies of Negative Symptom Dimensions in Schizophrenia.

Authors:  Anthony O Ahmed; Brian Kirkpatrick; Eric Granholm; Laura M Rowland; Peter B Barker; James M Gold; Robert W Buchanan; Tacina Outram; Miguel Bernardo; María Paz García-Portilla; Anna Mane; Emilio Fernandez-Egea; Gregory P Strauss
Journal:  Schizophr Bull       Date:  2022-05-07       Impact factor: 7.348

4.  The Important Role of Motivation and Pleasure Deficits on Social Functioning in Patients With Schizophrenia: A Network Analysis.

Authors:  Hui-Xin Hu; Wilson Y S Lau; Eugenia P Y Ma; Karen S Y Hung; Si-Yu Chen; Kin-Shing Cheng; Eric F C Cheung; Simon S Y Lui; Raymond C K Chan
Journal:  Schizophr Bull       Date:  2022-06-21       Impact factor: 7.348

5.  Deconstructing Negative Symptoms in Individuals at Clinical High-Risk for Psychosis: Evidence for Volitional and Diminished Emotionality Subgroups That Predict Clinical Presentation and Functional Outcome.

Authors:  Tina Gupta; Henry R Cowan; Gregory P Strauss; Elaine F Walker; Vijay A Mittal
Journal:  Schizophr Bull       Date:  2021-01-23       Impact factor: 9.306

6.  A Network of Psychopathological, Cognitive, and Motor Symptoms in Schizophrenia Spectrum Disorders.

Authors:  Bernardo Melo Moura; Geeske van Rooijen; Frederike Schirmbeck; Hanneke Wigman; Luís Madeira; Peter van Harten; Jim van Os; P Roberto Bakker; Machteld Marcelis
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 9.306

7.  The Puzzle of Functional Recovery in Schizophrenia-Spectrum Disorders-Replicating a Network Analysis Study.

Authors:  Bernardo Melo Moura; Adela-Maria Isvoranu; Veronika Kovacs; Geeske Van Rooijen; Therese Van Amelsvoort; Claudia J P Simons; Agna A Bartels-Velthuis; P Roberto Bakker; Machteld Marcelis; Lieuwe De Haan; Frederike Schirmbeck
Journal:  Schizophr Bull       Date:  2022-06-21       Impact factor: 7.348

8.  Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia.

Authors:  Michael Davidson; Jay Saoud; Corinne Staner; Nadine Noel; Sandra Werner; Elisabeth Luthringer; David Walling; Mark Weiser; Philip D Harvey; Gregory P Strauss; Remy Luthringer
Journal:  Schizophr Bull       Date:  2022-05-07       Impact factor: 7.348

9.  Network Analysis of Symptom Comorbidity in Schizophrenia: Relationship to Illness Course and Brain White Matter Microstructure.

Authors:  Hua Ye; Andrew Zalesky; Jinglei Lv; Samantha M Loi; Suheyla Cetin-Karayumak; Yogesh Rathi; Ye Tian; Christos Pantelis; Maria A Di Biase
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 9.306

Review 10.  Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets.

Authors:  Matej Ľupták; Danica Michaličková; Zdeněk Fišar; Eva Kitzlerová; Jana Hroudová
Journal:  World J Psychiatry       Date:  2021-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.